Innovassynth Technologies (India) Ltd reported a significant financial turnaround for H1 FY27, posting a profit of Rs 8.23 crore compared to a loss of Rs 31.32 crore in the same period last year. Revenue saw a sharp rise to Rs 106.88 crore, backed by an order book of Rs 137 crore. While geopolitical tensions and sales spillover impacted Q2 margins, management maintains a positive outlook for the second half of the fiscal year.
Innovassynth Technologies Reports H1 FY27 Profit of Rs 8.23 Crore
Revenue for H1 FY27 reached Rs 106.88 crore, while the company maintains an open order book of Rs 137 crore.
Reader Takeaway: Strong financial turnaround to profitability driven by healthy order visibility, despite Q2 margin pressure from supply costs.
What just happened
Innovassynth Technologies has delivered a robust financial performance for the half-year ended September 30, 2026. The company successfully reversed its year-ago loss of Rs 31.32 crore to report a profit of Rs 8.23 crore. Total revenue for the six-month period climbed to Rs 106.88 crore, a significant jump from the Rs 29.93 crore recorded in H1 FY26. EBITDA for the period stood at Rs 16.64 crore, against a loss of Rs 26.63 crore in the prior year.
Why this matters
The transition to a profit-making entity indicates improved operational efficiency and successful execution of projects. With an order book of Rs 137 crore—comprising Rs 73 crore in Life Sciences, Rs 55 crore in CDMO, and Rs 10 crore in Specialty Chemicals—the company possesses strong revenue visibility for the coming quarters.
Business and Operational Update
Management confirmed that manufacturing units underwent a 10-day planned shutdown for debottlenecking and capacity expansion. Despite this, the company successfully completed two major customer audits and secured an EcoVadis Gold Rating for the third consecutive year.
Management Commentary and Guidance
Q2 results were tempered by the spillover of scheduled sales into the subsequent quarter and rising raw material costs caused by geopolitical unrest in West Asia. However, management remains optimistic, stating that H2 FY27 performance is expected to outpace the first half as the current business pipeline matures.
Risks to watch
Investors should note the inherent volatility in the CDMO business, where revenue timing is subject to customer project milestones. Additionally, exposure to global supply chain disruptions and raw material price volatility due to international geopolitical developments remains a key risk factor for margins.